Experimental Merger Remedies And Pilot Enforcement Schemes

Introduction

Experimental merger remedies are merger-control measures designed not merely to eliminate an identified anticompetitive effect, but to test, adapt, and refine remedies over time. Instead of imposing a completely fixed remedy at the moment of clearance, a competition authority may use pilot programmes, phased obligations, temporary commitments, behavioural experiments, monitoring periods, review clauses, data-driven benchmarks, or sunset mechanisms.

This approach is increasingly relevant in digital and technology markets because conventional merger remedies can become obsolete quickly. A remedy that appears adequate at clearance may fail because of changing technology, algorithmic behaviour, network effects, new entry, data accumulation, or changes in consumer behaviour.

A pilot enforcement scheme therefore treats merger control partly as an adaptive regulatory process:

identify harm → impose provisional remedy → monitor market → measure outcomes → adjust remedy → terminate, extend, or strengthen intervention.

The principal legal challenge is to preserve certainty, proportionality, procedural fairness and judicial review while allowing competition authorities sufficient flexibility to respond to changing market conditions.

1. Meaning of Experimental Merger Remedies

An experimental merger remedy is a remedy containing an element of controlled testing or adaptive implementation.

Traditional merger remedies normally ask:

“What remedy permanently addresses the competitive problem created by this transaction?”

An experimental remedy asks:

“What intervention is most likely to address the competitive problem, and how can its effectiveness be tested and adjusted after implementation?”

Such remedies may include:

1. Pilot access obligations
2. Temporary interoperability requirements
3. Phased divestitures
4. Trial licensing arrangements
5. Algorithmic-access experiments
6. Data-sharing pilots
7. Behavioural monitoring periods
8. Periodic competitive reviews
9. Sunset clauses
10. Automatic escalation mechanisms
11. Independent monitoring trustees
12. Experimental market-access conditions

2. Why Experimental Remedies Are Becoming Important

A. Digital markets change rapidly

Traditional structural remedies assume that market conditions remain relatively stable.

Digital markets do not necessarily behave this way.

A merger may change:

• algorithms;
• data resources;
• API access;
• cloud infrastructure;
• interoperability;
• ranking systems;
• app-store policies;
• advertising technology;
• AI model capabilities;
• switching costs.

Consequently, a remedy designed today may be inadequate tomorrow.

B. Competitive effects may be difficult to predict

In technology mergers, authorities may not know with certainty:

• whether rivals will enter;
• whether users will multi-home;
• whether interoperability will actually reduce switching costs;
• whether access to data will facilitate entry;
• whether a platform will discriminate algorithmically;
• whether an innovation pipeline will remain independent.

Experimental remedies permit authorities to observe actual market outcomes rather than relying exclusively on ex ante predictions.

3. Core Components of a Pilot Enforcement Scheme

A well-designed experimental remedy normally contains six components.

1. Baseline

The authority identifies the competitive conditions existing before the remedy.

2. Intervention

A specific obligation is imposed.

3. Measurement

The authority establishes measurable indicators.

Examples include:

• entry rates;
• switching rates;
• API access;
• prices;
• quality;
• innovation;
• complaint levels;
• interoperability;
• data portability.

4. Monitoring

An independent trustee or authority evaluates compliance.

5. Review

The authority examines whether the remedy is working.

6. Adjustment

The remedy may be:

• continued;
• modified;
• expanded;
• reduced;
• replaced;
• terminated.

This produces an adaptive remedy architecture rather than a static remedy.

4. Experimental Remedies and Structural Remedies

Experimental remedies should not automatically replace structural remedies. Where a merger eliminates an independent competitor and divestiture is clearly effective, experimentation may be unnecessary.

5. Experimental Behavioural Remedies

Behavioural remedies are particularly suited to experimental enforcement.

An authority could require the merged firm to:

• provide non-discriminatory API access;
• maintain interoperability;
• refrain from self-preferencing;
• license technology;
• provide access to datasets;
• preserve technical interfaces;
• maintain existing contractual terms temporarily.

The authority could then measure whether these obligations preserve competitive opportunities.

6. Experimental Access Remedies

Access remedies can be designed as controlled pilots.

For example, following a technology merger:

Stage 1: selected competitors receive access.

Stage 2: the authority measures:

• quality;
• latency;
• entry;
• consumer switching;
• innovation.

Stage 3: access is expanded if the pilot works.

Stage 4: the authority modifies the access terms if foreclosure remains.

This is particularly relevant to:

• cloud computing;
• AI infrastructure;
• app stores;
• advertising exchanges;
• data platforms;
• interoperability services.

7. Experimental Data Remedies

Data may constitute a critical competitive resource.

Instead of permanently transferring a large dataset, an authority might require:

controlled access + purpose limitation + monitoring + periodic review.

This could test whether data access actually enables competitors to compete.

It also reduces the risk of unnecessarily imposing a permanent transfer of commercially sensitive information.

8. Algorithmic Remedies

Algorithmic merger remedies are particularly difficult because algorithms may change continuously.

A pilot scheme could require:

• algorithmic transparency to the regulator;
• independent testing;
• discrimination audits;
• ranking-impact monitoring;
• periodic reporting;
• controlled access to testing environments.

The authority could establish a regulatory sandbox in which the merged company tests changes before full implementation.

9. Sunset Clauses

A sunset clause provides that a remedy automatically expires after a specified period unless renewed.

For example:

A five-year interoperability obligation expires unless the authority determines that competitive conditions remain substantially impaired.

This prevents temporary emergency intervention from becoming permanent regulation without reassessment.

However, sunset clauses can create risks where:

• market foreclosure is difficult to detect;
• entry takes many years;
• network effects create irreversible damage.

10. Escalation Mechanisms

An experimental remedy can contain an automatic escalation mechanism.

For example:

Pilot access

↓

If entry increases → continue

↓

If entry remains weak → strengthen access

↓

If foreclosure persists → impose structural separation

This creates a remedy ladder.

Such a system can combine behavioural and structural remedies without immediately imposing the most intrusive intervention.

11. Six Important Case Laws

1. European Commission — Microsoft/LinkedIn

The Microsoft/LinkedIn merger is important for understanding data-driven and digital-market remedies.

The European Commission accepted commitments addressing concerns surrounding professional social-networking services and customer relationship management software.

The case illustrates how merger remedies can preserve access and interoperability where the competitive concern involves an ecosystem rather than merely a traditional physical asset.

Principle

Digital merger remedies may need to preserve interoperability and access conditions rather than simply transferring physical assets.

Relevance to experimental remedies

The Microsoft/LinkedIn framework demonstrates the movement toward remedies that depend on ongoing compliance and monitoring, an important foundation for adaptive enforcement.

2. Google/DoubleClick

The European Commission's examination of Google's acquisition of DoubleClick is important because it demonstrated the difficulty of evaluating mergers involving data, online advertising and rapidly evolving digital markets.

Although the transaction was cleared without the kind of experimental remedy contemplated here, the case is significant for showing why conventional merger analysis may struggle with:

• data accumulation;
• technological change;
• network effects;
• future competitive relationships.

Principle

The absence of an immediately measurable price effect does not eliminate the need to consider longer-term competitive consequences.

Experimental-remedy relevance

Where future effects are uncertain, monitoring and post-clearance review can become important components of enforcement design.

3. United States v. AT&T Inc. — Time Warner

The AT&T/Time Warner litigation provides an important illustration of the difficulty of predicting vertical merger effects.

The U.S. Department of Justice challenged the transaction, arguing that the combination could increase bargaining leverage over distributors.

The court ultimately allowed the transaction to proceed.

Principle

Vertical merger remedies require careful assessment of:

• foreclosure incentives;
• bargaining power;
• contractual relationships;
• dynamic market responses.

Experimental-remedy relevance

The case demonstrates why authorities may consider monitoring and behavioural safeguards when structural divestiture is not clearly justified.

4. Comcast/NBCUniversal

The Comcast/NBCUniversal transaction is particularly relevant to experimental enforcement.

The transaction raised concerns regarding:

• online video distribution;
• programming access;
• foreclosure;
• vertical integration;
• emerging competitors.

The U.S. authorities imposed extensive behavioural conditions.

Principle

Where a merger combines complementary levels of a supply chain, behavioural commitments may be used to preserve competitive access.

Experimental-remedy relevance

The case demonstrates the practical possibility of imposing time-limited, monitored obligations instead of relying exclusively on divestiture.

5. Google/ITA Software

The European Commission's clearance of Google's acquisition of ITA Software involved commitments addressing concerns in online travel search.

The case is significant because access to information and search functionality could affect downstream competitors.

Principle

A merger involving an important information infrastructure can create foreclosure concerns even where the transaction does not simply eliminate a traditional direct competitor.

Experimental-remedy relevance

The case illustrates why access commitments, monitoring and non-discrimination can be relevant tools in information-intensive markets.

6. Dow/DuPont

The Dow/DuPont merger is one of the most important examples of a large-scale structural remedy in modern merger control.

The European Commission required divestiture of significant overlapping businesses.

The case illustrates the conventional alternative to experimental remedies: remove the structural source of competitive harm.

Principle

Where competitive harm results from the elimination of important horizontal competition, structural divestiture may be superior to behavioural experimentation.

Experimental-remedy relevance

Dow/DuPont demonstrates an important limitation:

experimentation should not become an excuse for avoiding structural remedies where the competitive problem is identifiable and effectively removable through divestiture.

12. Additional Case Law Supporting Adaptive Enforcement

Several other merger decisions are useful in developing the doctrine.

Bayer/Monsanto

The European Commission required substantial divestitures to address concerns regarding agricultural inputs and innovation.

The case illustrates the importance of preserving innovation competition, not merely existing price competition.

Siemens/Alstom

The European Commission prohibited the merger.

The case demonstrates the limits of behavioural experimentation where the authority considers that commitments would not adequately restore effective competition.

Facebook/WhatsApp

The European Commission's treatment of data-related issues demonstrates the increasing relevance of data and information ecosystems in merger enforcement.

Microsoft/Activision Blizzard

The transaction generated extensive regulatory scrutiny concerning cloud gaming and access.

The resulting commitments illustrate how time-bound access and licensing obligations can be used to preserve competitive opportunities in rapidly evolving technology markets.

13. Pilot Enforcement and the Microsoft/Activision Model

The Microsoft/Activision transaction is especially useful for understanding contemporary experimental remedies.

The competitive concern centred substantially on cloud gaming.

The remedy architecture relied on licensing arrangements designed to preserve access to Activision Blizzard's games through competing cloud-gaming providers.

The significance is methodological:

rather than requiring immediate structural separation of the entire transaction, the remedy sought to preserve a specific competitive pathway.

This represents a movement toward targeted, measurable and technologically adaptable remedies.

14. Experimental Remedies in AI Mergers

AI mergers present particularly strong arguments for pilot enforcement.

Consider a hypothetical acquisition of an AI model developer by a dominant cloud platform.

Potential concerns include:

• compute foreclosure;
• model exclusivity;
• API discrimination;
• training-data restrictions;
• interoperability barriers;
• preferential inference pricing;
• tying between cloud and AI services.

Instead of requiring immediate divestiture, an authority might impose:

Phase I

Mandatory API access.

Phase II

Independent monitoring.

Phase III

Quarterly assessment of:

• access;
• prices;
• latency;
• model quality;
• switching;
• competitor entry.

Phase IV

Remedy adjustment.

Phase V

Structural intervention if the pilot fails.

15. Experimental Remedies and Innovation

Traditional merger remedies can sometimes unintentionally reduce innovation.

A divestiture may preserve current competition but disrupt:

• research teams;
• intellectual property;
• technical integration;
• economies of scale.

An experimental remedy can therefore attempt to preserve innovation incentives while constraining exclusionary conduct.

For example:

maintain independent R&D access for five years + prohibit discriminatory licensing + monitor innovation output.

However, measuring innovation is difficult.

Authorities must avoid relying solely on:

• number of patents;
• R&D expenditure;
• number of product launches.

They may also examine:

• product quality;
• technological performance;
• research diversity;
• time to innovation;
• successful market entry.

16. Experimental Remedies and Consumer Welfare

A pilot remedy should identify measurable consumer outcomes.

Potential indicators include:

Price

Whether prices rise following the merger.

Quality

Whether service quality deteriorates.

Choice

Whether consumers retain meaningful alternatives.

Innovation

Whether product development declines.

Switching

Whether consumers can realistically move between suppliers.

Privacy

In digital markets, whether privacy quality deteriorates.

Thus, consumer welfare can be treated as a multi-dimensional outcome rather than simply price.

17. Role of Independent Monitoring Trustees

Experimental remedies require reliable monitoring.

An independent trustee may:

• inspect compliance;
• collect data;
• interview competitors;
• investigate complaints;
• test interoperability;
• examine contractual practices;
• report to the authority.

The trustee effectively becomes the measurement mechanism of the experiment.

Without independent monitoring, an experimental remedy can become merely a self-reporting obligation.

18. Competition Authorities as Adaptive Regulators

Experimental merger remedies change the institutional role of the competition authority.

The authority moves from:

one-time merger decision-maker

toward:

continuing market-condition supervisor.

This creates institutional benefits but also raises concerns.

Benefits

• flexibility;
• evidence-based adjustment;
• technological responsiveness;
• reduced risk of over-remedying;
• ability to respond to unforeseen effects.

Risks

• regulatory uncertainty;
• administrative costs;
• excessive discretion;
• repeated intervention;
• weakened finality of merger clearance.

19. Due Process Concerns

Experimental enforcement must comply with procedural safeguards.

A company should know:

• what obligations apply;
• what data will be examined;
• what constitutes non-compliance;
• when review occurs;
• what triggers escalation;
• how long the remedy lasts.

A regulator should not be permitted to transform a limited merger commitment into an indefinite regulatory regime without appropriate legal authority.

20. Proportionality

Experimental remedies should satisfy proportionality.

Suitability

Can the remedy realistically address the identified harm?

Necessity

Is a less restrictive remedy available?

Balancing

Do the competitive benefits justify the compliance burden?

This is particularly important where the remedy affects:

• innovation;
• intellectual property;
• commercial confidentiality;
• technical architecture;
• investment incentives.

21. Experimental Remedies and Legal Certainty

There is an inherent tension:

Experimentation requires flexibility.

Merger law requires predictability.

The solution is to establish predefined adjustment rules.

For example:

If competitor access falls below X for two consecutive review periods, the merged firm must implement Y.

This is preferable to an entirely discretionary system.

22. Remedy Sandboxes

A particularly advanced form of experimental enforcement is a remedy sandbox.

Under such a model:

1. the authority identifies the competitive risk;
2. the merged firm proposes alternative compliance mechanisms;
3. competitors participate in testing;
4. the authority measures results;
5. the most effective mechanism becomes the permanent compliance framework.

This could be especially valuable for:

• AI;
• cloud computing;
• fintech;
• digital advertising;
• app stores;
• data portability.

23. Pilot Enforcement Schemes and Market Testing

Competition authorities can also use competitors as external evaluators.

Suppose a merged platform claims that API access is genuinely interoperable.

The authority can allow several independent competitors to test:

• technical access;
• latency;
• functionality;
• pricing;
• reliability.

If competitors cannot effectively use the interface, the remedy has failed even if the merged company technically complied with the written obligation.

This moves enforcement from formal compliance toward functional competition.

24. Risks of Experimental Merger Remedies

1. Regulatory uncertainty

Businesses may not know what obligations will ultimately apply.

2. Enforcement costs

Continuous monitoring can be expensive.

3. Information asymmetry

The merged company normally knows more about its technology than the regulator.

4. Strategic compliance

A company may technically comply while defeating the purpose of the remedy.

5. Regulatory capture

Long-term interaction between regulator and dominant firm may create institutional dependence.

6. False experimentation

Some competitive harms cannot safely be experimented with because once competition disappears it may be impossible to restore.

25. When Experimental Remedies Are Most Appropriate

They are particularly suitable where:

• harm is uncertain;
• markets are rapidly evolving;
• behavioural effects are measurable;
• competition can realistically be restored if the pilot fails;
• structural remedies would be disproportionately disruptive;
• access or interoperability is technically feasible.

They are less suitable where:

• the merger eliminates a unique competitor;
• market entry is extremely difficult;
• network effects are irreversible;
• competitive harm is highly predictable;
• divestiture provides a clear and effective solution.

26. A Proposed Experimental Merger-Remedy Framework

A competition authority could adopt the following framework:

Step 1 — Identify theory of harm

↓

Step 2 — Define measurable competitive indicators

↓

Step 3 — Select least restrictive effective remedy

↓

Step 4 — Establish pilot period

↓

Step 5 — Appoint independent monitor

↓

Step 6 — Collect market evidence

↓

Step 7 — Conduct periodic review

↓

Step 8 — Continue / modify / terminate

↓

Step 9 — Escalate if competitive harm persists

↓

Step 10 — Structural remedy if behavioural experimentation fails

This produces an adaptive enforcement hierarchy.

27. Key Legal Principles Emerging From the Case Law

The case law collectively supports several principles:

Principle 1 — Remedies must address the actual theory of harm

A generic behavioural commitment is insufficient where the competitive harm is specific.

Principle 2 — Structural remedies remain important

Experimental remedies should not substitute for divestiture where divestiture is clearly necessary.

Principle 3 — Digital markets require functional remedies

Access, interoperability and data conditions may be more important than traditional price commitments.

Principle 4 — Monitoring is central

A pilot without reliable monitoring cannot demonstrate whether competition has been preserved.

Principle 5 — Remedies should contain measurable outcomes

Vague obligations are difficult to enforce.

Principle 6 — Sunset and escalation mechanisms can balance flexibility and certainty

The authority should specify how the experiment ends or intensifies.

28. Relationship With Ex Ante and Ex Post Enforcement

Experimental merger remedies occupy a middle position between ex ante and ex post regulation.

Traditional ex ante merger control

Predict → decide → remedy → close case

Traditional ex post enforcement

Conduct occurs → investigate → impose sanction/remedy

Experimental merger control

Predict → intervene → observe → measure → adjust

This third model is particularly attractive for rapidly changing digital markets.

29. Overall Assessment

Experimental merger remedies represent a shift from static merger correction to adaptive competition governance.

Their greatest advantage is that they acknowledge uncertainty. Competition authorities cannot always accurately predict how a merger involving AI, data, cloud infrastructure, algorithms or digital ecosystems will affect competition over five or ten years.

Pilot schemes allow regulators to test whether an intervention actually works.

But experimentation has a critical boundary:

competition law should not experiment with irreversible competitive destruction.

Where a merger permanently removes an essential competitor or creates an irreversible concentration of market power, a structural remedy may be necessary.

The strongest model is therefore a graduated remedy system:

monitoring → pilot remedy → measurable review → adjustment → escalation → structural intervention where necessary.

Conclusion

Experimental merger remedies and pilot enforcement schemes provide competition authorities with a flexible mechanism for dealing with uncertainty, especially in digital and AI-driven markets. Their legitimacy depends upon clear theories of harm, measurable benchmarks, independent monitoring, proportionality, procedural safeguards, defined review periods and transparent escalation mechanisms.

The major lesson from cases such as Dow/DuPont, Comcast/NBCUniversal, Microsoft/LinkedIn, Google/ITA Software, AT&T/Time Warner and Microsoft/Activision Blizzard is that merger remedies increasingly have to address dynamic competitive processes rather than merely static market shares.

The future of merger control is therefore unlikely to be exclusively:

“approve or prohibit.”

It is increasingly capable of becoming:

“approve subject to a measurable, monitored and adaptable competitive experiment—with escalation where the experiment fails.”